Kalaris Therapeutics (KLRS) Amortizatization of Intangibles (2021 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Amortizatization of Intangibles of $220000.0 for Q1 2026, down 30.38% quarter-over-quarter from $316000.0 in Q4 2025.
Kalaris Therapeutics (KLRS) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Kalaris Therapeutics' Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $220000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles changed N/A year-over-year to $220000.0; the TTM figure through Mar 2026 stood at $660000.0 (changed N/A YoY), while the FY2025 annual figure was $399000.0, down 68.11% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $220000.0, down from $316000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $1.2 million in Q3 2023, with the low at -$76000.0 in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $349000.0 (2024), against an average of $468642.9.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles tumbled 99.5% in 2024, then surged 5166.67% in 2025.
- Kalaris Therapeutics' Amortizatization of Intangibles stood at $870000.0 in 2022, then surged by 39.31% to $1.2 million in 2023, then sank by 99.5% to $6000.0 in 2024, then soared by 5166.67% to $316000.0 in 2025, then sank by 30.38% to $220000.0 in 2026.
- Business Quant data shows KLRS's Amortizatization of Intangibles at $220000.0 in Q1 2026, $316000.0 in Q4 2025, and $6000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | 114,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 114,000.00 |
| Jun 30, 2026 | 114,000.00 |
| Mar 31, 2026 | 220,000.00 |
| Mar 31, 2026 | 220,000.00 |
| Dec 31, 2025 | 316,000.00 |
| Dec 31, 2025 | 316,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 118,000.00 |
| Sep 30, 2024 | 118,000.00 |
| Jun 30, 2024 | 382,000.00 |
| Jun 30, 2024 | 382,000.00 |
| Mar 31, 2024 | 745,000.00 |
| Mar 31, 2024 | 745,000.00 |
| Dec 31, 2023 | 1.21 Mn |
| Dec 31, 2023 | 1.21 Mn |
| Sep 30, 2023 | 1.23 Mn |
| Sep 30, 2023 | 1.23 Mn |
| Jun 30, 2023 | 524,000.00 |
| Jun 30, 2023 | 524,000.00 |